Aquinox Pharmaceuticals Inc
Comparing Cara Therapeutics’ Financial Performance
Financial performance In 3Q17, Cara Therapeutics (CARA) incurred $9.6 million in research and development expenses, compared with $9.1 million in 3Q16. This fall in expenses was due to a $3.1 million decrease in expenses for oral CR845’s Phase 2B clinical trial, and partially offset by increased expenses for its intravenous CR845 safety study. Meanwhile, the company’s general and administrative expenses rose from […]
Cara Therapeutics’ Collaboration Agreements
Oral CR845 for treating chronic kidney disease–associated pruritus In July 2017, Cara Therapeutics (CARA) announced the results from a Phase 1 safety and pharmacokinetics study of oral CR845 in patients with chronic kidney disease (or CKD) undergoing hemodialysis. The results showed that the four dosage strengths evaluated in the study were well tolerated. In October […]
Analysts’ Recommendations for Cara Therapeutics in January 2018
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus.
How Has Aquinox Performed Compared to Peers?
Aquinox has a positive future outlook and will likely continue to better its performance in the near future.
Aquinox Improves Net Income with New Discoveries
Aquinox Pharmaceuticals (AQXP) has achieved success in the field of discovery and development of new drugs.
Aquinox’s Journey from the Bottom to the Top
As per Aquinox’s 2Q15 earnings report, the company’s net income has gone up by 25.9% as compared to 1Q15 earnings of 20.76%.